Irbesartan: Second generation of ARB as metabosartan

Current Hypertension Reviews

Volumn 6, Issue 3, 2010, Pages 173-179

  Morishita, Ryuichi ^a   Kanda, Yasuhiko ^b   Nakajima, Masatoshi ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Angiotensin II; Hypertension; Metabolic syndrome; Obesity; PPAR

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; IRBESARTAN; LOSARTAN; METABOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 77958057393     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340210791936750     Document Type: Article

References (37)

1. Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a reviewof its use in hypertension and in the management of diabeticnephropathy. Drugs 2004; 64: 999-1028.
2. Bramlage P, Durand-Zaleski I, Desai N, Pirk N, Hacker C. Thevalue of irbesartan in the management of hypertension. ExpertOpin Pharmacother 2009; 10: 1817-31.
3. Kliewer SA, Forman BM, Blumberg B, et al. Differentialexpression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994; 91: 7355-59.
4. Spiegelman BM, Heinrich R. Biological control through regulatedtranscription coactivators. Cell 2004; 119: 157-67.
5. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensintype 1 receptor blockers induce peroxisome proliferator-activatedreceptor-γ activity. Circulation 2004; 109: 2054-7.
6. Schupp M, Clemenz M, Gineste R, et al. Molecular characterizationof new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-52.
7. Robinson JG. Should we use PPAR agonists to reduce cardiovascularrisk? PPAR Research 2008; 2008: Article ID 891425, 1-13.
8. Pershadsingh HA, Moore DM. PPAR γ Agonists: potential astherapeutics for neovascular retinopathies. PPAR Res 2008; 2008: Article ID 164273, 1-13.
9. Benson SC, Pershadsingh HA, Ho CI, et al. Identification oftelmisartan as a unique angiotensin II receptor antagonist withselective PPAR γ-modulating activity. Hypertension 2004; 43: 993-1002.
10. Goebel M, Clemenz M, Staels B, Unger T, Kintscher U, Gust R. Characterization of new PPARγ agonists: analysis of telmisartan'sstructural components. ChemMedChem 2009; 4: 445-6.
11. Pochetti G, Godio C, Mitro N, et al. Insights into the mechanismof partial agonism: crystal structures of the peroxisome proliferator-activated receptor γ ligand-binding domain in the complexwith two enantiomeric ligands. J Biol Chem 2007; 282: 17314-24.
12. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia,and renal injury: mechanisms and implications. Am J Nephrol 2006; 26: 232-44.
13. Wahba IM, Mak RH. Obesity and obesity-initiated metabolicsyndrome: mechanistic links to chronic kidney disease. Clin J AmSoc Nephrol 2007; 2: 550-62.
14. Zheng F, Guan Y. Thiazolidinediones: a novel class of drugs forthe prevention of diabetic nephropathy? Kidney Int 2007, 72: 1301-3.
15. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazonedecreases albuminuria in type 2 diabetic patients. Kidney Int 2007; 72: 1367-73.
16. Pershadsingh HA. Peroxisome proliferator-activated receptorgamma: therapeutic target for disease beyond diabetes: quo vadis? Expert Opinion Investigational Drugs 2004; 13: 215-28.
17. Cock TA, Houten SM, Auwerx J. Peroxisome proliferator-activatedreceptor-γ: too much of a good thing causes harm. EMBO Rep 2004; 5: 142-7.
18. Tham DM, Wang YX, Rutledge JC. Modulation of vascularinflammation by PPARs. Drug News Perspect 2003; 16: 109-16.
19. Nakamura T, Yamamoto E, Kataoka K, et al. Beneficial effectsof pioglitazone on hypertensive cardiovascular injury are enhancedby combination with candesartan. Hypertension 2008; 51: 296-301.
20. Namikoshi T, Tomita N, Satoh M, et al. Pioglitazone enhances theantihypertensive and renoprotective effects of candesartan inZucker obese rats fed a high-protein diet. Hypertens Res 2008; 31: 745-55.
21. Jin HM, Pan Y. Renoprotection provided by losartan in combinationwith pioglitazene is superior to renoprotection provided bylosartan alone in patients with type 2 diabetic nephropathy. KidneyBlood Press Res 2007; 30: 203-11.
22. de las Heras N, Martin-Fernandez B, Miana M, et al. The protectiveeffect of irbesartan in rats fed a high fat diet is associated withmodification of leptin-adiponectin imbalance. J Hypertens 2009; 27(suppl 6): S37-S41.
23. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartanfor the treatment of hypertension in patients with the metabolicsyndrome: a sub analysis of the treat to target post authorizationsurvey. Prospective observational, two armed study in 14,200patients. Cardiovasc Diabetol 2007; 6: 12.
24. Parhofer KG, Münzel F, Krekler M. Effect of the angiotensinreceptor blocker irbesartan on metabolic parameters in clinicalpractice: the DO-IT prospective observational study. CardiovascDiabetol 2007; 6: 36.
25. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role ofrenin-angiotensin-aldosterone system in the progression of chronickidney disease. Kidney Int 2005; 68(suppl 99): S57-S65.
26. Raij L. The pathophysiologic basis for blocking the reninangiotensinsystem in hypertensive patients with renal disease. AmJ Hypertens 2005; 18: 95S-9S.
27. Engeli S, Scling P, Gorzelniak K, et al. The adipose-tissue reninangiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807-25.
28. Information on New Drug Application, Irbesartan. Pharmaceuticaland Medical Devices Agency 2008; (http://www.info.pmda.go.jp/shinyaku/g080407/index.html).
29. Takayama F, Saito K, Yoshinaga T, et al. Metabolic fate of losartan,a new angiotensin II receptor antagonist (1): absorption, distribution,metabolism and excretion after single administration in rats. Xenohio Metabol Dispos 1995; 10: 223-43.
30. Information on New Drug Application, Telmisartan. Pharmaceuticaland Medical Devices Agency 2002; (http://www.info.pmda.go.jp/shinyaku/g021008/index.html?submit=%C9%BD%BC%A8).
31. Information on New Drug Application, Valsartan. Japan PharmacistsEducation Center 2000; (http://www.jpec.or.jp/contents/c01/link.html).
32. Kondo T, Yoshida K, Yoshimura Y, et al. Disposition of the newangiotensin II receptor antagonist candesartan cilexetil in rats anddog. Arzneim-Forsch/Drug Res 1996; 46: 594-600.
33. Information on New Drug Application, Olmesartan. Pharmaceuticaland Medical Devices Agency 2004; (http://www.info.pmda.go.jp/shinyaku/g040105/index.html?submit=%C9%BD%BC%A8).
34. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotectiveeffect of the angiotensin-receptor antagonist irbesartan in patientswith nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
35. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect ofirbesartan on the development of diabetic nephropathy in patientswith type 2 diabetes. N Engl J Med 2001; 345: 870-8.
36. Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan tomaintain sinus rhythm in patients with long-lasting persistent atrialfibrillation: a prospective and randomized study. Circulation 2002; 106: 331-6.
37. Yusuf S. A randomized evaluation of irbesartan versus placeboin patients with atrial fibrillation (factorial design of ACTIVEprogram). European Society of Cardiology 2009; (http://www.escardio.org/congresses/esc-2009/congress-reports/Pages/708005-708006-yusuf-brugada.aspx).